The best opportunity is when the other folks are panicking, but you keep your head. And that time is right. Now.Thanks for reading my research. If you want to learn even more about my research process and what stocks I like, check out my subscription marketplace service Concentrated Value with MVI . You'll get:Harrow, Inc. ( HROW ) is an emerging powerhouse in FDA approved branded ophthalmic pharmaceuticals. The company began in 2015 as an ophthalmic compounding pharmacy and now dominates this tiny niche wi ...

公司核心行动 - 礼来公司宣布通过其直接面向消费者平台LillyDirect降低畅销减肥药Zepbound单剂量小瓶的现金价格 [1] - 起始剂量价格降至每月299美元，较之前价格349美元下降 [2] - 5毫克剂量价格定为每月399美元，所有其他剂量价格定为每月449美元，较之前统一价格499美元下降 [2] 行业竞争动态 - 主要竞争对手诺和诺德在几周前也宣布了其肥胖和糖尿病药物的额外现金价格折扣 [1] - 诺和诺德将肥胖药Wegovy和糖尿病药Ozempic的现金价格从每月499美元降至349美元 [7] - 诺和诺德为新现金支付患者推出临时 introductory offer，前两个月两种药物的最低两个剂量每月199美元 [8] 市场背景与准入障碍 - Zepbound的标价约为每月1086美元，高标价和美国保险覆盖不均是患者获取药物的主要障碍 [3] - 直接面向消费者销售现已占Zepbound新处方量的三分之一以上 [7] 政策环境影响 - 特朗普政府与礼来和诺和诺德签署协议，旨在使GLP-1药物更易获取和负担 [4] - 协议内容包括降低政府购药价格、首次为部分患者引入Medicare对肥胖药物的覆盖，以及于1月推出的政府直接面向消费者网站TrumpRx提供折扣药 [4] - 礼来与政府的协议主要针对多剂量笔式注射器形式的Zepbound，需待FDA批准 [5] 产品形式与可及性策略 - 单剂量小瓶形式需患者使用注射器和针头自行注射，礼来于2024年8月首次推出该形式的Zepbound [6] - 降低现有单剂量小瓶价格可使更多患者更快获得折扣治疗 [5] - 公司计划继续提供更多选择，包括扩展输送设备选择和创建新的获取途径 [6]

Study findings to be featured in a poster spotlight presentationHOUSTON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the acceptance of an abstract for poster spotlight (with oral) presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Anto ...

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac ConditionsDecember 01, 2025 7:27 AM EST | Source: Cardiol Therapeutics Inc.Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evid ...

Britain and the United States are poised to agree to zero tariffs on pharmaceutical products, with an announcement due at the White House on Monday, according to two sources familiar with the matter. ...

A promising obesity and diabetes drug stumbles in Alzheimer's trials, rattling markets. Did investors overreact, or is this a reset for long-term opportunity?Novo Nordisk (NVO +1.31%) is a Danish pharmaceutical company that's been around for about a century. It specializes in developing medications for metabolic diseases, such as diabetes and obesity treatment. Most of us have probably heard of their primary products, which include Ozempic and Wegovy. Both of these treatments contain an active ingredient ca ...

Accessibility StatementSkip Navigation TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26, 2025, it received confirmation from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1). This achievement aligns with RedHill's ongoing strategic init ...

Transaction boosts Solta Medical's position to meet rising demand in China's growing aesthetics market LAVAL, QC / ACCESS Newswire / December 1, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, along with its global aesthetic business, Solta Medical, today announced the successful completion of the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., consisting of the Shibo group's aesthetics distribution business. ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 million, inclusive of a cash upfront and equity investment from Regeneron; companies to share worldwide development costs and future profits 50:50Collaboration combines Regeneron’s long-standing expertise in genetics, genetic medicines and clinical development with Tessera’s pioneering Gene WritingTM and non-viral d ...

A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event. About Karyopharm Therapeutics Accessibility StatementSkip Navigation NEWTON, Mass., Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's ...